Relationship of lipoproteins to cardiovascular events: The aim-high trial (atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes)

Journal of the American College of Cardiology

Volumn 62, Issue 17, 2013, Pages 1580-1584

  Guyton, John R ^a   Slee, April E ^b   Anderson, Todd ^c   Fleg, Jerome L ^d   Goldberg, Ronald B ^e   Kashyap, Moti L ^f,k   Marcovina, Santica M ^g   Nash, Stephen D ^h   O'Brien, Kevin D ^g   Weintraub, William S ⁱ   Xu, Ping ^b   Zhao, Xue Qiao ^g   Boden, William E ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Axio Research   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

ⁱ Center for Heart and Vascular Health   (United States)

^j STRATTON VA MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

cardiovascular events; clinical trial; GPR109A; lipoproteins; niacin

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEATH; DRUG DOSE ESCALATION; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

CARDIOVASCULAR; CARDIOVASCULAR EVENTS; CLINICAL TRIAL; CV; ER; EXTENDED-RELEASE; G-PROTEIN-COUPLED RECEPTOR 109A; GPR109A; HAZARD RATIO; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HR; LDL-C; LIPOPROTEINS; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; NIACIN; TG; TRIGLYCERIDE;

AGED; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NIACIN; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIGLYCERIDES; WORLD HEALTH;

EID: 84886000801     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.023     Document Type: Article

References (22)

1. Aim-High Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
2. R. Haynes, L. Jang, and J.C. Hopewell HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
3. Armitage J. HPS2-THRIVE: randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Presented at: American College of Cardiology Annual Scientific Sessions; March 9, 2013; San Francisco, CA.
4. J.M. Lee, M.D. Robson, and L.M. Yu Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J Am Coll Cardiol 54 2009 1787 1794
5. A.J. Taylor, T.C. Villines, and E.J. Stanek Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
6. Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease J Am Med Assoc 231 1975 360 381
7. L.A. Carlson, and G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
8. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
9. E.J. Whitney, R.A. Krasuski, and B.E. Personius A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events Ann Intern Med 142 2005 95 104
10. B. Lauring, A.K. Taggart, and J.R. Tata Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression Sci Transl Med 4 2012 148ra115
11. L.H. Zhang, V.S. Kamanna, S.H. Ganji, X.M. Xiong, and M.L. Kashyap Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells J Lipid Res 53 2012 941 950
12. L.A. Carlson Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review J Intern Med 258 2005 94 114
13. M. Lukasova, C. Malaval, A. Gille, J. Kero, and S. Offermanns Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells J Clin Invest 121 2011 1163 1173
14. J.E. Digby, F. Martinez, and A. Jefferson Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms Arterioscler Thromb Vasc Biol 32 2012 669 676
15. S.H. Ganji, S. Qin, L. Zhang, V.S. Kamanna, and M.L. Kashyap Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells Atherosclerosis 202 2009 68 75
16. J. Neyman, and E. Pearson On the problem of the most efficient tests of statistical hypotheses Philos Trans Roy Soc London Series A 231 1933 289 337
17. L.M. Kassalow Likelihood ratio tests for regression coefficients from the Cox proportional hazards model using the phreg procedure. SAS Conference Proceedings: SAS Users Group International 18 1993 SAS Cary, NC
18. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
19. G.L. Vega, N.B. Cater, S. Meguro, and S.M. Grundy Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia Am J Cardiol 95 2005 1309 1313
20. L.A. Carlson, L. Levi, and L. Oro Plasma lipids and urinary excretion of catecholamines in man during experimentally induced emotional stress, and their modification by nicotinic acid J Clin Invest 47 1968 1795 1805
21. P. Penev, K. Spiegel, T. Marcinkowski, and E. Van Cauter Impact of carbohydrate-rich meals on plasma epinephrine levels: dysregulation with aging J Clin Endocrinol Metab 90 2005 6198 6206
22. J.J. Albers, A.E. Slee, and K.D. O'Brien Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1575 1579